Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.

ctDNA was detectable at one or more timepoints in 15/42 (36%), including 11/20 (55%) with stage III and 4/22 (18%) with stage II disease. Radiographic recurrence occurred in 7/42 patients, 6 of whom were ctDNA-positive. 26/27 (96%) patients with persistent ctDNA negativity remained clinically and radiographically progression-free. Twelve of 15 ctDNA-positive patients received adjuvant immunotherapy or treatment escalation after a positive result; 6 had sustained clearance.

ASCO Annual Meeting 2023